相关学者
相关机构
Primary Immune Thrombocytopenia in Elderly Patients in the Era of Emerging Technologies: Towards an Integrated and Personalized Medicine
Primary Immune Thrombocytopenia in Elderly Patients in the Era of Emerging Technologies: Towards an Integrated and Personalized Medicine
ES评分0
| DOI | 10.20900/agmr20260002 |
| 刊名 |
AGMR
|
| 年，卷(期) | 2026, 8(1) |
| 作者 |
|
| 作者单位 |
Department of Internal Medicine, Hôpital de Hautepierre, University Hospital of Strasbourg, 67000 Strasbourg, France ; |
| 摘要 |
Primary immune thrombocytopenia (ITP) is entering a new era shaped by precision medicine, digital health, and geroscience, with key implications for patients ≥65 years. In this population, therapy balances efficacy with minimizing systemic toxicity and age-related complications. Corticosteroids are used cautiously due to metabolic, infectious, and neuropsychiatric risks, while thrombopoietin receptor agonists (TPO-RAs) have become preferred for long-term management. Individualized targets (~50–100 ×10⁹/L) aim to ensure hemostasis while limiting thrombotic risk. Advances in immunogenetics, transcriptomics, and pharmacogenomics improve patient stratification and prediction of treatment response and relapse. Artificial intelligence and Big Data applied to integrated clinical and omics datasets support diagnosis, risk modeling, and personalized therapy sequencing. Geriatric-specific assessment—including frailty, fall risk, polypharmacy, cognition, and adherence—combined with digital longitudinal monitoring, enhances preventive care. These innovations underpin the concept of geriatric–immune systemic ITP (G-ITP), framing ITP in older adults as a systemic disorder influenced by immunosenescence, clonal hematopoiesis, endothelial dysfunction, and frailty rather than isolated autoimmunity. Integrating comprehensive geriatric assessment with personalized TPO-RA therapy may improve outcomes and reduce morbidity, establishing ITP as a model for geroscience-informed, patient-centered immune care.
|
| Abstract |
Primary immune thrombocytopenia (ITP) is entering a new era shaped by precision medicine, digital health, and geroscience, with key implications for patients ≥65 years. In this population, therapy balances efficacy with minimizing systemic toxicity and age-related complications. Corticosteroids are used cautiously due to metabolic, infectious, and neuropsychiatric risks, while thrombopoietin receptor agonists (TPO-RAs) have become preferred for long-term management. Individualized targets (~50–100 ×10⁹/L) aim to ensure hemostasis while limiting thrombotic risk. Advances in immunogenetics, transcriptomics, and pharmacogenomics improve patient stratification and prediction of treatment response and relapse. Artificial intelligence and Big Data applied to integrated clinical and omics datasets support diagnosis, risk modeling, and personalized therapy sequencing. Geriatric-specific assessment—including frailty, fall risk, polypharmacy, cognition, and adherence—combined with digital longitudinal monitoring, enhances preventive care. These innovations underpin the concept of geriatric–immune systemic ITP (G-ITP), framing ITP in older adults as a systemic disorder influenced by immunosenescence, clonal hematopoiesis, endothelial dysfunction, and frailty rather than isolated autoimmunity. Integrating comprehensive geriatric assessment with personalized TPO-RA therapy may improve outcomes and reduce morbidity, establishing ITP as a model for geroscience-informed, patient-centered immune care.
|
| 关键词 |
immune thrombocytopenia; elderly patients; geriatric assessment; artificial intelligence (ai); predictive medicine; molecular biology; polypharmacy; thrombotic risk; personalized medicine
|
| KeyWord |
immune thrombocytopenia; elderly patients; geriatric assessment; artificial intelligence (ai); predictive medicine; molecular biology; polypharmacy; thrombotic risk; personalized medicine
|
| 基金项目 | |
| 页码 | - |
- 参考文献
- 相关文献
1.González-López TJ, Provan D. The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments. Blood Rev. 2025;73:101300. doi: 10.1016/j.blre.2025.101300
2.Singh A, Uzun G, Bakchoul T. Primary immune thrombocytopenia: Novel insights into pathophysiology and disease management. J Clin Med. 2021;10(4):789. doi: 10.3390/jcm10040789
3.Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematol
[Internet]. 2025;04(6):1112–23. Available from: https://haematologica.org/article/view/8925.
4.Crickx E, Mahévas M, Michel M, Godeau B. Older adults and immune thrombocytopenia: Considerations for the clinician. Clin Interv Aging. 2023;18:115–30. doi: 10.2147/CIA.S369574
5.Steurer M, Quittet P, Papadaki HA, Selleslag D, Viallard JF, Kaiafa G, et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice. Eur J Haematol. 2017;98(2):112–20. doi: 10.1111/ejh.12807
6.Lv Y, Shi H, Liu H, Zhou L. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently? Front Immunol. 2022;13:953716. doi: 10.3389/fimmu.2022.953716
7.Shen N, Qiao J, Jiang Y, Yan J, Wu R, Yin H, et al. Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: A systematic review and meta‑analysis of randomized controlled trials. Biomed Rep. 2024;20(3):44. doi: 10.3892/br.2024.1732
8.Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018;93(12):1501–8. doi: 10.1002/ajh.25275
9.Liu F-Q, Chen Q, Qu Q, Sun X, Huang Q-S, He Y, et al. Machine-Learning Model for Resistance/Relapse Prediction in immune thrombocytopenia using gut microbiota and function signatures. Blood 2021;138 (Suppl 1):18. doi: 10.1182/blood-2021-148987
10.Jurja S, Negreanu-Pirjol T, Vasile M, Mehedinti Hincu M, Coviltir V, Negreanu-Pirjol B-S. Xanthophyll pigments dietary supplements administration and retinal health in the context of increasing life expectancy trend. Front Nutr. 2023;10:1226686. doi: 10.3389/fnut.2023.1226686
11.Andrès E, El Hassani Hajjam A, Maloisel F, Alonso-Ortiz MB, Méndez-Bailón M, Lavigne T, et al. Artificial Intelligence (AI) and Drug-Induced and Idiosyncratic Cytopenia: The role of AI in prevention, prediction, and patient participation. Hematol Rep. 2025;17(3):24. doi: 10.3390/hematolrep17030024
12.Fishbein JN, Nisotel LE, MacDonald JJ, Amoyal Pensak N, Jacobs JM, Flanagan C, et al. Mobile application to promote adherence to oral chemotherapy and symptom management: A Protocol for design and development. JMIR Res Protoc. 2017;6(4):e62. doi: 10.2196/resprot.6198
- 文献评论